Bank Of America Corp Nuvalent, Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 94,244 shares of NUVL stock, worth $8.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,244

Previous 90,261 4.41%

Holding current value

$8.99 Million

Previous $6.78 Million 5.49%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$62.76 - $81.61 $249,973 - $325,052	3,983 Added 4.41%	94,244 $7.15 Million
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $24,237 - $29,811	-335 Reduced 0.37%	90,261 $6.78 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $1.68 Million - $3.18 Million	39,658 Added 77.86%	90,596 $6.67 Million
Q2 2023 Aug 14, 2023	SELL	$23.58 - $44.68 $763,308 - $1.45 Million	-32,371 Reduced 38.86%	50,938 $2.15 Million
Q1 2023 May 12, 2023	BUY	$25.42 - $33.52 $519,203 - $684,646	20,425 Added 32.48%	83,309 $2.17 Million
Q4 2022 Feb 10, 2023	BUY	$18.46 - $36.37 $562,660 - $1.11 Million	30,480 Added 94.06%	62,884 $1.87 Million
Q3 2022 Nov 14, 2022	BUY	$13.55 - $19.92 $101,760 - $149,599	7,510 Added 30.17%	32,404 $630,000
Q2 2022 Aug 12, 2022	SELL	$7.4 - $15.07 $150,197 - $305,875	-20,297 Reduced 44.91%	24,894 $337,000
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $121,684 - $204,408	10,445 Added 30.06%	45,191 $627,000
Q4 2021 Feb 08, 2022	BUY	$18.01 - $30.1 $617,292 - $1.03 Million	34,275 Added 7277.07%	34,746 $662,000
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $8,595 - $18,062	471 New	471 $11,000

Others Institutions Holding NUVL

# of Institutions

179

Shares Held

56.6M

Call Options Held

527K

Put Options Held

131K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $4.1B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Nuvalent, Inc. Transaction History